Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Telemedicine and the “Zoom effect” boost big-cap medtech
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Boston deadheads its Lotus
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Orthopaedics companies’ nightmare quarter
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
